Anzeige
Mehr »
Freitag, 26.06.2026 - Börsentäglich über 12.000 News
Tagebau oder Tiefsee-Bergbau: Für welchen Fußabdruck entscheidet sich die Welt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0EAT9 | ISIN: BE0003818359 | Ticker-Symbol: GXE
Tradegate
26.06.26 | 10:56
24,980 Euro
-1,19 % -0,300
Branche
Biotechnologie
Aktienmarkt
BEL Mid
AMX
1-Jahres-Chart
LAKEFRONT BIOTHERAPEUTICS NV Chart 1 Jahr
5-Tage-Chart
LAKEFRONT BIOTHERAPEUTICS NV 5-Tage-Chart
RealtimeGeldBriefZeit
24,96025,00011:14
24,94025,00011:11

Aktuelle News zur LAKEFRONT BIOTHERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
16.06.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
09.06.Lakefront BioTherapeutics launches €50M share buyback program1
09.06.Lakefront Biotherapeutics: Lakefront Announces Initiation of €50 Million Stock Repurchase Program414Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the "Program")...
► Artikel lesen
09.06.Gilead And Lakefront Biotherapeutics Complete Ouro Medicines Acquisition To Advance Autoimmune Disease Pipeline5
08.06.Lakefront Biotherapeutics: Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer203Mechelen, Belgium; June 8, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership...
► Artikel lesen
08.06.Gilead Sciences und Lakefront Biotherapeutics schließen Übernahme von Ouro Medicines ab und bauen damit ihre Entzündungspipeline weiter aus3
05.06.Gilead Sciences, Lakefront Biotherapeutics Acquire Ouro Medicines9
LAKEFRONT BIOTHERAPEUTICS Aktie jetzt für 0€ handeln
05.06.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer2
04.06.Gilead, Lakefront Biotherapeutics complete Ouro Medicines acquisition6
04.06.Gilead and Lakefront Biotherapeutics complete Ouro Medicines acquisition5
04.06.Gilead Sciences, Inc.: Gilead Sciences and Lakefront Biotherapeutics Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline1.505- Companies will collaborate on the development of gamgertamig, a potential first-in-class and best-in-class T cell engager in autoimmune diseases - Gilead Sciences, Inc. (Nasdaq: GILD) and Lakefront...
► Artikel lesen
27.05.Lakefront Biotherapeutics NV - 6-K, Report of foreign issuer1
26.05.Lakefront Biotherapeutics: Lakefront Receives Transparency Notification from Bank of America722Mechelen, Belgium; May 26, 2026, 22.01 CET; regulated information - Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America. Pursuant to...
► Artikel lesen
13.05.Galapagos NV: Namensänderung in Lakefront Biotherapeutics NV14
07.05.Galapagos Q1 2026 presentation: Ouro deal, rebranding highlight transformation16
06.05.Galapagos GAAP EPS of $0.20 beats by $1.72, revenue of $6.5M16
06.05.GALAPAGOS NV - 6-K, Report of foreign issuer-
06.05.Galapagos NV: Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update850Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager...
► Artikel lesen
29.04.GALAPAGOS NV - 6-K, Report of foreign issuer-
Weiter >>
71 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1